Company Performance - AtriCure reported a quarterly loss of $0.02 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.17 per share a year ago, resulting in an earnings surprise of +86.67% [1] - The company achieved revenues of $136.14 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.61% and showing a year-over-year increase from $116.27 million [2] - Over the last four quarters, AtriCure has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Outlook - AtriCure shares have increased approximately 8.7% since the beginning of the year, slightly outperforming the S&P 500's gain of 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $129.12 million, and for the current fiscal year, it is -$0.50 on revenues of $522.61 million [7] Industry Context - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of AtriCure's stock may be influenced by the overall outlook for the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $136 million, reflecting a 17% year-over-year increase and a 10.1% sequential growth from Q1 2025 [4][18] - Adjusted EBITDA was $15.4 million, compared to $7.8 million in Q2 2024, indicating significant profitability improvement [23] - Cash generation for the quarter was nearly $18 million, with cash and investments totaling $117.8 million at the end of Q2 2025 [4][23] Business Line Data and Key Metrics Changes - Appendage management revenue grew over 20%, with U.S. sales of appendage management products reaching $45.1 million, up 18.9% year-over-year [6][19] - Pain management franchise grew nearly 43%, driven by the CryoSphere Max and CryoSphere Plus probes, with U.S. sales at $21.2 million, reflecting a 41.1% increase [14][20] - Open ablation product sales were $36.5 million, up 18.6% year-over-year, led by the Encompass clamp [19][11] Market Data and Key Metrics Changes - U.S. revenue was $110.6 million, a 15.7% increase from Q2 2024, with international sales showing strong growth across all franchises [18][21] - European sales accounted for $16.1 million, up 27.7%, while Asia Pacific and other international markets contributed $9.4 million, up 16.3% [21] Company Strategy and Development Direction - The company is focused on innovation, with new product launches such as the AtriClip Flex Mini and CryoStere Max driving growth [5][14] - The completion of the LEAPS clinical trial enrollment is expected to enhance the standard of care for stroke prevention in cardiac surgery [9][10] - The company anticipates continued growth in international markets, outpacing U.S. growth, driven by new product launches and increased adoption of existing products [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $527 million to $533 million for 2025, reflecting growth of approximately 13% to 15% [24][27] - The company expects to maintain gross margins comparable to 2024, with adjusted EBITDA projected to be between $49 million and $52 million for the full year [27][24] - Management acknowledged challenges in the minimally invasive hybrid therapy market due to increased adoption of PFA catheter technology but remains optimistic about long-term growth opportunities [13][48] Other Important Information - The company is preparing for the launch of the Cryo XD probe for pain management in lower limb amputations, with initial procedures completed [15][16] - The company is also focused on expanding clinical and economic data to support the value of non-opioid pain management solutions [16] Q&A Session Summary Question: Impact of LEAPS trial completion on physician utilization - Management indicated that the completion of the LEAPS trial has had minimal impact on overall revenue, with continued growth in appendage management adoption [32][34] Question: Managing discussions with electrophysiologists regarding PFA failures - Management emphasized open and transparent discussions with electrophysiologists, focusing on the clinical benefits of PFA and the importance of follow-up solutions [37][39] Question: Guidance implications for top-line growth - Management clarified that guidance reflects a conservative approach, with expectations for continued strong performance driven by new product launches and international growth [43][45] Question: Trends in minimally invasive hybrid therapy - Management acknowledged significant pressure in the hybrid therapy segment but highlighted the overall strength of the business in achieving 17% growth [48][50] Question: Progress on Cryosphere MAX adoption - Management reported that Cryosphere MAX is in over half of U.S. accounts, with cautious optimism for similar uptake in Europe [55][57] Question: Key milestones for clinical initiatives - Management outlined upcoming milestones for LEAPS, BOX No AF, and PFA programs, with expectations for first patient enrollment in BOX No AF this year [66][70]

Financial Performance - Second quarter revenue reached $136.1 million, a 17.1% increase year-over-year (16.5% on a constant currency basis)[3, 10] - U S revenue increased by $15.0 million, or 15.7%, to $110.6 million compared to the second quarter of 2024[3] - International revenue grew by $4.8 million, or 23.3% (19.9% on a constant currency basis), reaching $25.6 million[3] - Gross profit for the second quarter was $101.5 million, compared to $86.8 million in the second quarter of 2024[4] - Adjusted EBITDA for the second quarter was $15.4 million, an increase of $7.6 million from the second quarter of 2024[5, 10] - Net loss improved by $1.8 million year-over-year, with a net loss of $6.2 million[10] Financial Guidance - Full year 2025 revenue is projected to be approximately $527 million to $533 million[6] - Full year 2025 Adjusted EBITDA is expected to be approximately $49 million to $52 million[6] - Full year 2025 adjusted loss per share is expected to be in the range of $0.34 to $0.39[6] Key Products and Developments - Growth was driven by key product lines, including the AtriClip® FLEX·Mini ™ device, the EnCompass® clamp, and the cryoSPHERE MAX ™ probe[3] - Enrollment was completed for all 6,500 patients in the LeAAPS trial[10]

[Executive Summary](index=1&type=section&id=Executive%20Summary) AtriCure reported strong Q2 2025 financial results driven by innovation and portfolio expansion, with significant revenue growth, improved profitability, and a major clinical trial milestone [Second Quarter 2025 Highlights](index=1&type=section&id=Second%20Quarter%202025%20Highlights) AtriCure reported strong second quarter 2025 results, marked by significant revenue growth, improved net loss, and increased Adjusted EBITDA, alongside the completion of a major clinical trial - Worldwide revenue reached **$136.1 million**, an increase of **17.1%** year over year (**16.5%** on a constant currency basis)[6](index=6&type=chunk) - Net loss improved to **$6.2 million**, an improvement of **$1.8 million** year over year[6](index=6&type=chunk) - Adjusted EBITDA was **$15.4 million**, an increase of **$7.6 million** year over year[6](index=6&type=chunk) - The company generated **$17.9 million** of cash in the quarter[6](index=6&type=chunk) - Completed enrollment of all **6,500 patients** in the LeAAPS trial[6](index=6&type=chunk) [CEO Commentary](index=1&type=section&id=CEO%20Commentary) CEO Michael Carrel emphasized that the strong Q2 results are a testament to AtriCure's innovation and the expanding impact of its product portfolio, particularly the AtriClip platform and cryoSPHERE devices, which are driving adoption and improving patient outcomes - The stellar results reflect the power of innovation and the growing impact of the expanding portfolio, especially the AtriClip platform and cryoSPHERE device offerings[2](index=2&type=chunk) - New technologies are driving deeper adoption, reduced procedure times, and improved patient outcomes, leading to increasing momentum[2](index=2&type=chunk) - The company is optimistic about delivering strong growth and expanding profitability in the second half of 2025 and beyond[2](index=2&type=chunk) [Second Quarter 2025 Financial Results](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Results) AtriCure's Q2 2025 financial results show robust revenue growth across segments, improved net loss, and strong non-GAAP performance, despite a slight gross margin decrease [Revenue Performance](index=1&type=section&id=Revenue%20Performance) AtriCure achieved a total revenue of $136.1 million in Q2 2025, representing a 17.1% increase year-over-year, driven by robust growth in both U.S. and international markets across key product lines Q2 2025 Total Revenue Overview | Metric | Q2 2025 | Q2 2024 | YoY Change | YoY Change (Constant Currency) | | :----- | :------ | :------ | :--------- | :----------------------------- | | Total Revenue | $136.1 million | $116.3 million | 17.1% | 16.5% | [U.S. Revenue](index=1&type=section&id=U.S.%20Revenue) U.S. revenue grew by 15.7% to $110.6 million, primarily driven by strong sales in open ablation, pain management, and appendage management product lines U.S. Revenue by Product Line (Q2 2025 vs Q2 2024) | Product Line | Q2 2025 (in thousands) | Q2 2024 (in thousands) | YoY Change | | :----------- | :--------------------- | :--------------------- | :--------- | | Open ablation | $36,468 | $30,760 | 18.5% | | Minimally invasive ablation | $7,839 | $11,828 | -33.7% | | Pain management | $21,168 | $15,006 | 41.1% | | Appendage management | $45,108 | $37,945 | 18.9% | | **Total U.S. Revenue** | **$110,583** | **$95,539** | **15.7%** | - U.S. revenue growth was primarily driven by sales across key product lines, including the AtriClip FLEX·Mini device for appendage management, the EnCompass clamp for open ablation, and the cryoSPHERE MAX probe for post-operative pain management[3](index=3&type=chunk) [International Revenue](index=1&type=section&id=International%20Revenue) International revenue surged by 23.3% to $25.6 million, with significant growth across all product franchises and geographic regions International Revenue by Product Line (Q2 2025 vs Q2 2024) | Product Line | Q2 2025 (in thousands) | Q2 2024 (in thousands) | YoY Change | | :----------- | :--------------------- | :--------------------- | :--------- | | Open ablation | $10,349 | $9,170 | 12.9% | | Minimally invasive ablation | $2,372 | $1,764 | 34.5% | | Pain management | $2,033 | $1,241 | 63.8% | | Appendage management | $10,802 | $8,555 | 26.3% | | **Total International Revenue** | **$25,556** | **$20,730** | **23.3%** | - International revenue increased by **23.3%** (**19.9%** on a constant currency basis) to **$25.6 million**, realizing significant growth across all franchises and geographic regions[3](index=3&type=chunk) [Profitability and Net Loss](index=1&type=section&id=Profitability%20and%20Net%20Loss) AtriCure demonstrated improved profitability in Q2 2025, reducing its loss from operations and net loss per share compared to the prior year, despite a slight decrease in gross margin due to product mix Q2 2025 Profitability Metrics | Metric | Q2 2025 (in thousands) | Q2 2024 (in thousands) | YoY Change | | :----- | :--------------------- | :--------------------- | :--------- | | Gross Profit | $101,482 | $86,844 | 16.8% | | Gross Margin | 74.5% | 74.65% | -0.15 percentage points | | Loss from Operations | $(6,192) | $(7,168) | Improved by $976 | | Net Loss | $(6,190) | $(8,008) | Improved by $1,818 | | Basic and Diluted Net Loss Per Share | $(0.13) | $(0.17) | Improved by $0.04 | - Gross margin for the second quarter 2025 was **74.5%**, a decrease of **15 basis points** from the second quarter 2024, reflecting less favorable geographic and product mix[3](index=3&type=chunk) [Non-GAAP Financial Measures (Q2)](index=1&type=section&id=Non-GAAP%20Financial%20Measures%20(Q2)) In Q2 2025, AtriCure reported significant improvements in its non-GAAP financial metrics, with Adjusted EBITDA more than doubling and adjusted loss per share substantially decreasing compared to the prior year Q2 2025 Non-GAAP Financial Metrics | Metric | Q2 2025 | Q2 2024 | YoY Change | | :----- | :------ | :------ | :--------- | | Adjusted EBITDA | $15.4 million | $7.8 million | Increased by $7.6 million | | Adjusted Loss Per Share | $(0.02) | $(0.17) | Improved by $0.15 | [2025 Financial Guidance](index=1&type=section&id=2025%20Financial%20Guidance) AtriCure has updated its full-year 2025 financial guidance, projecting increased revenue and Adjusted EBITDA, alongside an improved adjusted loss per share [2025 Financial Guidance](index=1&type=section&id=2025%20Financial%20Guidance) AtriCure has raised its financial outlook for the full year 2025, projecting higher revenue and Adjusted EBITDA, alongside an improved adjusted loss per share and modest cash flow generation Full Year 2025 Financial Guidance | Metric | Projected Full Year 2025 | | :----- | :----------------------- | | Revenue | $527 million to $533 million | | Adjusted EBITDA | $49 million to $52 million | | Adjusted Loss Per Share | $(0.34) to $(0.39) | - Management expects modest cash flow generation for the full year 2025[5](index=5&type=chunk) [Company Overview](index=2&type=section&id=Company%20Overview) This section provides an overview of AtriCure's core business in Afib and pain management technologies, along with important disclosures regarding forward-looking statements and associated risks [About AtriCure](index=2&type=section&id=About%20AtriCure) AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, serving a global market of over 59 million Afib patients. The company's portfolio includes FDA-approved devices and minimally invasive therapies - AtriCure provides innovative technologies for the treatment of Afib and related conditions, which affect more than **59 million people** worldwide[8](index=8&type=chunk) - Key products include the **FDA-approved Isolator Synergy™ Ablation System** for persistent Afib, the widely sold AtriClip Left Atrial Appendage Exclusion System, Hybrid AF™ Therapy, and cryoICE cryoSPHERE probes for pain relief[8](index=8&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) This section serves as a cautionary note, indicating that statements regarding future events are forward-looking and subject to various risks and uncertainties that could cause actual results to differ materially from projections - Except for historical information, certain statements are forward-looking and subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from projections[9](index=9&type=chunk) - Risks include market acceptance, negative clinical data, competition, regulatory approvals, impacts of rising healthcare costs, and the ability to manage intellectual property rights, as detailed in SEC filings[9](index=9&type=chunk) [Use of Non-GAAP Financial Measures](index=2&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) This section explains AtriCure's use of non-GAAP financial measures to provide supplemental insights into operational performance, emphasizing their limitations and the need for GAAP reconciliation [Use of Non-GAAP Financial Measures](index=2&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) AtriCure uses non-GAAP financial measures like constant currency revenue, Adjusted EBITDA, and Adjusted loss per share to provide supplemental insights into its financial performance, believing these metrics offer a more comparable view of operational results by excluding certain non-operating or non-recurring items. Investors are cautioned to review GAAP reconciliations and not rely solely on non-GAAP measures - Non-GAAP financial measures are provided to supplement GAAP statements, offering additional and meaningful assessments of revenue and operational results[10](index=10&type=chunk)[11](index=11&type=chunk) - These measures have limitations as analytical tools and should not be considered in isolation or as a substitute for GAAP financial results[16](index=16&type=chunk) [Constant Currency Revenue Definition](index=2&type=section&id=Constant%20Currency%20Revenue%20Definition) Constant currency revenue is a non-GAAP metric used to evaluate growth by adjusting for the non-operating impact of foreign currency exchange rate fluctuations - Constant currency revenue is a non-GAAP measure calculated by applying previous period foreign currency exchange rates to comparable periods to better measure comparability of results[11](index=11&type=chunk) - Management analyzes revenue on a constant currency basis to evaluate growth, as changes in foreign currency exchange rates have a non-operating impact[11](index=11&type=chunk) [Adjusted EBITDA Definition](index=2&type=section&id=Adjusted%20EBITDA%20Definition) Adjusted EBITDA is a non-GAAP measure reflecting core business operations by excluding non-cash and non-recurring charges from net loss - Adjusted EBITDA is calculated as net loss before other income/expense, income tax expense, depreciation and amortization, share-based compensation, and non-recurring charges[12](index=12&type=chunk) - Non-recurring charges include acquisition costs, acquired-in-process research and development (IPR&D), legal settlement costs, impairment of intangible assets, and changes in fair value of contingent consideration liabilities[12](index=12&type=chunk) - Management uses Adjusted EBITDA for strategic and annual operating planning, believing it reflects ongoing core business operations[14](index=14&type=chunk) [Adjusted Loss Per Share Definition](index=3&type=section&id=Adjusted%20Loss%20Per%20Share%20Definition) Adjusted loss per share is a non-GAAP metric that modifies net loss per share by excluding specific non-cash and non-recurring adjustments - Adjusted loss per share is a non-GAAP measure that calculates net loss per share before non-cash adjustments for fair value of contingent consideration liabilities, acquired IPR&D, legal settlement costs, impairment of intangible assets, and debt extinguishment[15](index=15&type=chunk) [Condensed Consolidated Financial Statements](index=4&type=section&id=Condensed%20Consolidated%20Financial%20Statements) This section presents AtriCure's unaudited condensed consolidated statements of operations and balance sheets for Q2 2025 and prior periods, detailing financial performance and position [CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This section presents AtriCure's unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2025 and 2024, detailing revenue, expenses, and net loss under GAAP Condensed Consolidated Statements of Operations (Three Months Ended June 30) | Metric (in thousands) | Q2 2025 | Q2 2024 | | :-------------------- | :------ | :------ | | Total revenue | $136,139 | $116,269 | | Cost of revenue | $34,657 | $29,425 | | Gross profit | $101,482 | $86,844 | | Research and development expenses | $29,284 | $20,416 | | Selling, general and administrative expenses | $78,390 | $73,596 | | Total operating expenses | $107,674 | $94,012 | | Loss from operations | $(6,192) | $(7,168) | | Net loss | $(6,190) | $(8,008) | | Basic and diluted net loss per share | $(0.13) | $(0.17) | Condensed Consolidated Statements of Operations (Six Months Ended June 30) | Metric (in thousands) | YTD Q2 2025 | YTD Q2 2024 | | :-------------------- | :---------- | :---------- | | Total revenue | $259,759 | $225,120 | | Cost of revenue | $65,649 | $57,008 | | Gross profit | $194,110 | $168,112 | | Research and development expenses | $51,812 | $40,261 | | Selling, general and administrative expenses | $154,444 | $145,936 | | Total operating expenses | $206,256 | $186,197 | | Loss from operations | $(12,146) | $(18,085) | | Net loss | $(12,937) | $(21,277) | | Basic and diluted net loss per share | $(0.27) | $(0.45) | [CONDENSED CONSOLIDATED BALANCE SHEETS](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides AtriCure's unaudited condensed consolidated balance sheets as of June 30, 2025, and December 31, 2024, outlining the company's assets, liabilities, and stockholders' equity Condensed Consolidated Balance Sheets (as of June 30, 2025 vs. December 31, 2024) | Metric (in thousands) | June 30, 2025 | December 31, 2024 | | :-------------------- | :------------ | :---------------- | | **Assets:** | | | | Cash and cash equivalents | $117,796 | $122,721 | | Total current assets | $271,257 | $267,826 | | Total Assets | $608,849 | $609,328 | | **Liabilities & Equity:** | | | | Total current liabilities | $68,843 | $73,424 | | Total Liabilities | $144,358 | $148,359 | | Total Stockholders' Equity | $464,491 | $460,969 | [Reconciliation of Non-GAAP to GAAP Results](index=6&type=section&id=Reconciliation%20of%20Non-GAAP%20to%20GAAP%20Results) This section provides detailed reconciliations of AtriCure's non-GAAP financial measures, including Adjusted EBITDA and Adjusted Loss Per Share, to their most directly comparable GAAP equivalents [Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)](index=6&type=section&id=Reconciliation%20of%20Adjusted%20EBITDA) This section provides the reconciliation of GAAP net loss to non-GAAP Adjusted EBITDA for the three and six months ended June 30, 2025 and 2024, detailing adjustments for income tax, depreciation, share-based compensation, and acquired IPR&D Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA) (Three Months Ended June 30) | Metric (in thousands) | Q2 2025 | Q2 2024 | | :-------------------- | :------ | :------ | | Net loss, as reported | $(6,190) | $(8,008) | | Income tax expense | $261 | $253 | | Other income (expense), net | $(263) | $587 | | Depreciation and amortization expense | $5,171 | $4,527 | | Share-based compensation expense | $11,371 | $10,391 | | Acquired in-process research & development expense | $5,000 | — | | **Non-GAAP adjusted income (adjusted EBITDA)** | **$15,350** | **$7,750** | [Reconciliation of Non-GAAP Adjusted Loss Per Share](index=6&type=section&id=Reconciliation%20of%20Adjusted%20Loss%20Per%20Share) This section presents the reconciliation of GAAP net loss to non-GAAP Adjusted Loss Per Share for the three and six months ended June 30, 2025 and 2024, highlighting adjustments for acquired IPR&D and loss on debt extinguishment Reconciliation of Non-GAAP Adjusted Loss Per Share (Three Months Ended June 30) | Metric (in thousands) | Q2 2025 | Q2 2024 | | :-------------------- | :------ | :------ | | Net loss, as reported | $(6,190) | $(8,008) | | Acquired in-process research & development expense | $5,000 | — | | Loss on debt extinguishment | — | — | | **Non-GAAP adjusted net loss** | **$(1,190)** | **$(8,008)** | | Basic and diluted adjusted net loss per share | $(0.02) | $(0.17) | [Additional Information](index=1&type=section&id=Additional%20Information) This section provides details for accessing the upcoming conference call to discuss financial results and contact information for investor relations inquiries [Conference Call](index=1&type=section&id=Conference%20Call) AtriCure will host a conference call to discuss its second quarter 2025 financial results, providing details for accessing the webcast and replay - AtriCure will host a conference call at **4:30 p.m. Eastern Time** on **Tuesday, July 29, 2025**, to discuss second quarter 2025 financial results[6](index=6&type=chunk) - The webcast can be accessed via the Investors page of AtriCure's corporate website (https://ir.atricure.com/events-and-presentations/events), with a replay available for **90 days**[6](index=6&type=chunk)[7](index=7&type=chunk) [CONTACTS](index=3&type=section&id=CONTACTS) This section provides contact information for investor relations inquiries - Investor relations contacts are Angie Wirick (Chief Financial Officer, AtriCure, Inc.) and Marissa Bych (Gilmartin Group)[17](index=17&type=chunk)

Company Overview - Astellas Pharma Inc. (ALPMY) is a notable stock in the Medical sector, which consists of 998 individual stocks and ranks 6 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperforming the market in the near term [3] Performance Analysis - Astellas Pharma's full-year earnings consensus estimate has increased by 15.3% over the past quarter, reflecting improved analyst sentiment and earnings outlook [4] - Year-to-date, Astellas Pharma has gained approximately 1%, while the average loss in the Medical group is about 2.4%, showcasing its better performance relative to the sector [4] Industry Context - Astellas Pharma belongs to the Medical - Drugs industry, which includes 164 companies and currently ranks 71 in the Zacks Industry Rank [6] - The Medical - Drugs industry has seen an average gain of 3% year-to-date, indicating that Astellas Pharma is slightly underperforming its industry peers [6] Comparative Analysis - Another stock, AtriCure (ATRC), has outperformed the sector with an 8.1% gain year-to-date and has a Zacks Rank of 2 (Buy) [5] - AtriCure is part of the Medical - Products industry, which has 83 stocks and ranks 140, with an average gain of 5.7% since the beginning of the year [7]

AtriCure (ATRC) FY Conference Summary Company Overview - **Company**: AtriCure (ATRC) - **Date of Conference**: June 09, 2025 - **Key Speaker**: Angie Weirich, Chief Financial Officer Key Points and Arguments Industry and Market Dynamics - AtriCure operates in the cardiac surgery and electrophysiology markets, focusing on atrial fibrillation (AFib) treatment and pain management solutions [3][4][19] - The company emphasizes the importance of preventative care in cardiac surgery, highlighting the LEAPS clinical trial and BOXNOAF trial as significant initiatives [3][4][22] Product Portfolio and Innovations - AtriCure's product portfolio includes PFA catheters and the AtriClip device, which are critical in the treatment of AFib and appendage management [4][20] - The company launched the AtriClip Flex Mini and Cryosphere Max probes, contributing to a 14% overall growth in the first quarter [39][28] - AtriCure is focused on expanding its appendage management franchise, with a new generation of AtriClip devices that are smaller and less invasive [20][21] Financial Performance and Growth Projections - AtriCure projects a top-line growth of 11% to 13% for the year, with a strong start at 14% [37][39] - The company is committed to improving profitability alongside double-digit revenue growth, despite facing challenges in the minimally invasive business segment [5][12][38] - The international business is growing rapidly but poses a margin headwind, with potential impacts of 10 to 40 points on margin depending on the country [49][50] Competitive Landscape - AtriCure faces competition from other less invasive treatments, particularly in the PFA catheter space, which has led to distractions for electrophysiologists (EPs) [6][13][40] - The CONVERGE clinical trial is positioned as a durable option for long-standing persistent AFib patients, despite initial challenges in adoption post-launch [10][12][14] Strategic Focus and Future Outlook - The company is prioritizing resource allocation towards its appendage management and pain management segments, while maintaining a cautious approach to the CONVERGE product line [24][28] - AtriCure is exploring new markets, including below-the-knee amputations, with the Cryo XT device set to launch later this year [29][30] - The long-term revenue target is set at $1 billion by 2030, with a focus on accelerating growth through clinical trials and market expansion [69][70] Operational Efficiency and Cost Management - AtriCure is focused on leveraging SG&A expenses and improving gross margins through new product launches and operational efficiencies [58][60] - The company has made significant investments in R&D, particularly in the LEAPS clinical trial, which is expected to yield long-term benefits [61][73] Capital Allocation and M&A Strategy - AtriCure is currently focused on organic growth opportunities rather than acquisitions, emphasizing the importance of maintaining profitability [81][82] - The company is cautious about pursuing M&A that could negatively impact its bottom line trajectory [82] Additional Important Insights - The company is seeing an increase in new accounts despite the competitive pressures from PFA technology [17][24] - AtriCure's approach to training and education for healthcare practitioners has evolved, focusing on impactful methods to enhance customer engagement [62][63] - The management remains optimistic about the future, aiming to continue expanding its addressable market and driving revenue growth [84]

Company Overview - Astellas Pharma Inc. is part of the Medical sector, which includes 997 individual stocks and currently holds a Zacks Sector Rank of 4 [2] - The company is classified under the Medical - Drugs industry, which consists of 161 companies and is ranked 52 in the Zacks Industry Rank [6] Performance Analysis - Astellas Pharma Inc. has a Zacks Rank of 1 (Strong Buy), indicating a positive outlook based on earnings estimates and revisions [3] - Over the past 90 days, the Zacks Consensus Estimate for Astellas Pharma's full-year earnings has increased by 20.7%, reflecting improved analyst sentiment [4] - Year-to-date, Astellas Pharma has returned approximately 0.3%, outperforming the Medical sector, which has seen an average loss of 7.1% [4] Comparative Analysis - AtriCure, another stock in the Medical sector, has a year-to-date return of 7% and a Zacks Rank of 2 (Buy) [5] - The Medical - Products industry, where AtriCure is categorized, has a ranking of 147 and has increased by 3.8% since the beginning of the year [7] - In contrast, Astellas Pharma's industry has underperformed slightly, with an average loss of 2% year-to-date [6]

Core Viewpoint - AtriCure (ATRC) shows potential for significant upside, with a mean price target of $49.89 indicating a 54.7% increase from its current price of $32.25 [1] Price Targets and Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $6.37, suggesting variability among analysts [2] - The lowest estimate of $40 indicates a 24% increase, while the highest estimate suggests an 86.1% surge to $60 [2] - Analysts' consensus on price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about AtriCure's earnings, with a positive trend in earnings estimate revisions indicating potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 25.1%, with four estimates moving higher and no negative revisions [12] - AtriCure holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a starting point for further research [10]

Creating a World Class Platform Investor Presentation April 2025 © 2025 AtriCure, Inc. All rights reserved. Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain "forward-looking statements," which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, AtriCure's expected market opportunity, guidance, future business, f ...

Revenue and Profitability - Worldwide revenue for Q1 2025 was $123,620, representing a 13.6% increase compared to $108,851 in Q1 2024[63] - Gross profit for Q1 2025 was $92,628, with a gross margin of 74.9%, up from 74.7% in Q1 2024[70] - Revenue for the three months ended March 31, 2025, was $123,620 million, a 13.6% increase from $108,851 million in the same period of 2024[70] - Gross profit increased to $92,628 million, representing a gross margin of 74.9%, compared to 74.7% in the prior year[70][71] - Net loss for the quarter was $6,747 million, an improvement from a net loss of $13,269 million in the prior year[70] Expenses - Research and development expenses increased by $2,683, or 13.5%, primarily due to clinical trial expenses related to the LeAAPS trial[72] - Selling, general and administrative expenses rose by $3,714, or 5.1%, driven by increased personnel costs[73] - Research and development expenses rose by $2,683 million, or 13.5%, primarily due to increased clinical trial costs and personnel expenses[72] - Selling, general and administrative expenses increased by $3,714 million, or 5.1%, driven by higher personnel costs[73] Clinical Trials and Product Development - The Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction (LeAAPS) trial has over 5,100 patients enrolled, with completion expected in H2 2025[66] - The Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction (LeAAPS) clinical trial has enrolled over 5,100 patients, with completion expected in the second half of 2025[66] - The AtriClip PRO-Mini LAA Exclusion System is expected to launch later in 2025 following FDA 510(k) clearance[69] - The FDA granted 510(k) clearance for the AtriClip PRO-Mini LAA Exclusion System, expected to launch later in 2025[69] - The cryoICE cryoXT™ probe received FDA clearance and is expected to launch later in 2025, designed for Cryo Nerve Block therapy[69] - The company continues to invest in research and development of new products and pursue regulatory approvals globally[64] Cash Flow and Debt - Cash and cash equivalents as of March 31, 2025, were $99,885, with outstanding debt of $61,865[74] - Net cash used in operating activities decreased by $9,990 from 2024 to 2025, reflecting improved operating results[77] - The company had unused borrowing capacity of $61,885 million as of March 31, 2025[74][81] - As of March 31, 2025, the company has borrowed $61,865 under its asset-based revolving credit facility, with unused borrowing availability of $61,885[81] - The company has a $125,000 asset-based revolving credit facility with an option to increase by an additional $40,000[80] Market and Economic Conditions - International sales increased by 20.8% (23.9% on a constant currency basis), driven by growth in appendage management, open ablation, and pain management[70] - The company is closely monitoring macroeconomic conditions, including inflationary pressures and rising interest rates, that may impact liquidity and access to capital resources[83] - Future capital requirements will depend on market acceptance of products, regulatory costs, and potential acquisitions[83] - The company anticipates that substantially all revenue will relate to products currently sold or in development[61] - The company anticipates that substantially all of its revenue for the foreseeable future will relate to products currently sold or in development[61]